[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"placebo---control\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:placebo---control":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,42,79,118,149,179,191,216,254],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100054259","the-effects-of-exogenous-ketones-on-cognitive-function-100054259",false,"NCT07051655","The Effects of Exogenous Ketones on Cognitive Function","Inclusion Criteria:\n\n* Age 19-55 years\n* BMI 30-40 (obese group) or 18-25 (lean and athlete groups)\n* Sedentary status (\\\u003C2 hrs\u002Fweek of structured physical activity) for obese and lean groups\n* Active athlete status (≥5 days\u002Fweek of structured activity) for athlete group\n\nExclusion Criteria:\n\n* Diagnosed neurological conditions (e.g., Parkinson's disease, multiple sclerosis, schizophrenia, muscular dystrophy, stroke, cerebral palsy)\n* History of seizures\n* Use of medications for diabetes, mood disorders, or attention disorders\n* Pregnant or breastfeeding\n* Current or recent use (within 1 month) of exogenous ketone supplements or adherence to a ketogenic diet",true,"ALL","19 Years","55 Years",{"count":20,"type":21},45,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to evaluate the acute effects of exogenous ketone monoester (KME) supplementation on cognitive function in three groups of adults aged 19-55 years: (1) obese, sedentary individuals; (2) lean, sedentary individuals; and (3) lean individuals who engage in regular physical activity (e.g., collegiate or amateur athletes). The main questions it aims to answer are to:\n\n* Assess the effects of acute KME supplementation versus placebo on cognitive, sensorimotor, and functional outcomes within groups.\n* Compare cognitive performance across the three groups.\n\nThe primary outcome is cognitive performance assessed using the NIH Toolbox Cognition Battery. Secondary Outcomes include sensorimotor performance, measured using the Senaptec Sensory System, and driving performance, assessed with a driving simulator.",[27,28],"Placebo - Control","Ketone Monoester","RECRUITING","2026-07-10",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":33},"2025-12-01",{"date":37,"type":21},"2027-07-31",{"name":39,"class":40},"University of Alabama at Birmingham","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100642134","phase-4-ironcare-iron-treatment-in-older-patients-with-hip-fractures-100642134","NCT07659184","IRONCARE: Iron Treatment in Older Patients With Hip Fractures","IRONCARE: Iron Treatment in Older Patients With Hip Fractures - A Double-blinded Placebo-controlled Randomized Trial","Inclusion Criteria:\n\n* Hip fracture (ICD-10 codes: DS720, DS721 and DS722)\n* Low energy trauma\n* Age ≥ 75 years\n* Hemoglobin ≤7.0 mmol\u002FL (11 g\u002FdL) during hospital admission\n\nExclusion Criteria:\n\n* Pathological fracture\n* Periprosthetic fracture\n* Inability to understand or speak Danish\n* Dysphagia and thus inability to swallow study medication\n* Signs of iron overload, hemochromatosis, or hemosiderosis\n* Liver disease (cirrhosis or hepatitis) and transaminase levels \\>3 times upper limit of normal\n* Known allergy to iron formulations\n* Severe asthma\n* Severe hypophosphatemia: \\\u003C0.35 mmol\u002FL\n* Patients already receiving iron supplementation that cannot be paused for the study period\n* Cognitive impairment that results in either memantine-treatment or a Short Portable Mental Status Questionnaire (SPMSQ) score \\> 4","75 Years",{"count":51,"type":21},528,[53],"PHASE4","The aim of this study is to investigate the effects of intravenous (IV) iron therapy compared to alternate-day oral iron treatment and no supplementation in older patients with hip fractures. This study will examine the impact of iron treatment on fatigue, functional decline, fear of falling, cognitive impairment, and quality of life, as well as its effects on iron stores and hemoglobin levels, with the overall goal of improving postoperative rehabilitation.\n\nThe trial will be conducted on five different hospitals in the Central Region of Denmark (Region Midtjylland).",[56,57,58,27],"Hip Fracture","Anemia","Iron",[60,57,61,62,63,64,65,66,67],"Hip fracture","iron","Intravenous iron","mobility","fatigue","hemoglobin","RCT","Placebo","NOT_YET_RECRUITING","2026-06-19",{"date":71,"type":33},"2026-06-24",{"date":73,"type":21},"2026-10-01",{"date":75,"type":21},"2028-09-30",{"name":77,"class":40},"University of Aarhus",5,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":15,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":92,"conditions":93,"keywords":100,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":4},"100637590","effects-of-creatine-and-heat-exposure-on-exercise-performance-and-body-water-distribution-100637590","NCT07593014","Effects of Creatine and Heat Exposure on Exercise Performance and Body Water Distribution","Creatine Monohydrate Supplementation During Repeated Heat Exposure: Effects on Fluid Balance and Exercise Performance in a Randomized Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Healthy biological males between 18 and 27 years of age\n* Recreationally active males and varsity athletes\n* Able to safely participate in moderate-intensity exercise and heat exposure\n* Willing to maintain habitual diet and physical activity throughout the study\n* Willing to refrain from additional dietary supplementation during study participation\n* Able to attend all required laboratory visits and heat exposure sessions\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* History of cardiovascular, metabolic, respiratory, renal, neurological, or heat-related illness\n* Contraindications to exercise testing or heat exposure identified during health screening\n* Current musculoskeletal injury limiting exercise participation\n* Current use of creatine supplementation or inability to complete the required washout period\n* Current use of medications or supplements known to affect hydration, thermoregulation, cardiovascular function, or exercise performance\n* Known allergy or intolerance to creatine monohydrate, maltodextrin, or orange juice\n* Inability to comply with study procedures or supplementation protocol\n* Resting tympanic temperature ≥38.0°C prior to a heat exposure session\n* Participation in another research study that may interfere with this protocol","MALE","18 Years","27 Years",{"count":90,"type":21},25,[24],"The goal of this clinical trial is to learn whether creatine supplementation changes how the body adapts to repeated exercise in the heat in healthy recreationally active adults and varsity athletes. The study will also examine whether creatine affects fluid balance, blood volume changes and exercise performance.\n\nThe main questions it aims to answer are:\n\nDoes creatine supplementation increase plasma volume and total body water during repeated heat exposure more than placebo? Does creatine supplementation improve exercise performance after heat acclimation more than placebo? Does creatine supplementation influence cardiovascular responses to heat stress?\n\nResearchers will compare a creatine supplementation group to a placebo group to determine whether creatine changes the magnitude of heat acclimation adaptations.\n\nParticipants will:\n\nComplete baseline measurements of body composition, hydration, blood markers, and exercise performance.\n\nConsume either creatine monohydrate or a placebo supplement daily Complete repeated supervised exercise sessions in a controlled heated environment Undergo repeated assessments of body water, temperature, heart rate, and exercise performance throughout the study",[94,95,96,97,98,27,99],"Heat Exposure","Exercise Performance","Hydration","Body Fluid Compartments","Creatine Supplementation","Plasma Volume",[101,94,102,103,99,104,97,105,106,107,108],"Creatine Monohydrate","Heat Acclimation","Short Term Heat Acclimation","Fluid Balance","Wingate Test","VO2 Max","Cardiorespiratory Performance","Musculoskeletal Performance","2026-05-11",{"date":111,"type":33},"2026-05-18",{"date":113,"type":21},"2026-07-30",{"date":115,"type":21},"2027-08-30",{"name":117,"class":40},"University of Windsor",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":15,"sex":16,"minAge":87,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":41},"100627704","early-phase-1-what-is-the-role-of-type-iiiiv-muscle-afferents-in-airway-resistance-and-thermoregulatory-responses-to-exercise-100627704","NCT07452094","What is the Role of Type III\u002FIV Muscle Afferents in Airway Resistance and Thermoregulatory Responses to Exercise?","Type III\u002FIV Muscle Afferents in Airway and Thermoregulatory Responses","Inclusion Criteria:\n\n* regularly physically active as determined via questionnaires (Par-Q \\& You)\n* maximal aerobic power 30 mL\u002Fmin\u002Fkg (female), 40 mL\u002Fkg\u002Fmin (male)\n\nExclusion Criteria:\n\n* current smokers\n* acute bronchial asthma\n* diabetics\n* chronic back pain\n* peripheral neuropathy\n* chronic obstructive airway or status asthmaticus\n* obese (body mass index \\> 30 kg\u002Fm2)\n* convulsive disorders\n* requiring daily medications that may affect responses to exercise (e.g. anti-hypertensive, anti-arrhythmogenics, blood thinners)\n* history of drug abuse\n* history of disease\u002Fdysfunction that could cause complication with exercise (e.g. cardiovascular, respiratory, neurological, musculoskeletal)\n* irregular or absent menstrual cycle\n* pregnant or suspected pregnancy\n* adverse response to physical exercise\n* current or history of esophageal or gastric disease, or frequent heart burn (\\>2x per week)\n* Lidocaine allergy","40 Years",{"count":127,"type":21},15,[129],"EARLY_PHASE1","Exercise places serious demands on the body. These demands are fundamentally caused by increases in oxygen demand and the consequent increase in body temperature. These demands are met by several physiological responses, including increases in heart rate, blood pressure, breathing and blood flow. These responses must be proportional to the increase in demand and some signal must relay information from the muscle to the brain. Group III\u002FIV afferents do just this. They relay information about the muscle (movement, temperature, acidity, etc.) up to the brain so that appropriate responses are mounted. There is strong evidence in animals that group III\u002FIV afferents play a key role in making breathing easier (decreasing airway resistance) and initiating sweating and blood flow responses. There has been no research on the role of group III\u002FIV afferents on these fundamental exercise responses in humans. The investigators propose to isolate the role of group III\u002FIV afferents on regulate airway resistance, sweating and blood flow responses to exercise in humans.",[27,132],"Experimental",[134,135,136,137,138,139],"Group III\u002FIV afferents","exercise","thermoregulation","sweating","blood flow","airway resistance","2026-02-27",{"date":142,"type":33},"2026-03-05",{"date":144,"type":21},"2026-04-01",{"date":146,"type":21},"2027-04-01",{"name":148,"class":40},"Northern Arizona University",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":15,"sex":16,"minAge":156,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":162,"conditions":163,"keywords":166,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":4},"100626270","phase-1-the-effects-of-psilocybin-in-healthy-volunteers-psychological-biochemical-and-electrophysiological-biomarkers-100626270","NCT07433452","The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers.","PSILOBIOMARKER","Inclusion Criteria:\n\n* Male or Female adults ages 21-65 at the time of screening.\n* Females of childbearing potential must have a negative pregnancy test at all designated visits.\n* Have a self-reported interest in psychedelic drugs and altered states of consciousness.\n* Never have used a classic, serotonergic psychedelic (such as psilocybin, psilocybin, LSD, or ayahuasca) or a dissociative anesthetic such as ketamine or PCP), or maximum one experience 5 years before the study starting without untoward effects.\n* Participants must be free of current or past substance use dependence or disorders, as determined by a semi-structured clinical interview for DSM-5 diagnoses (SCID-DSM-5).\n* Have a Body Max Index (BMI) 18-34 kg\u002Fm2 and an abdomen circumference ≤ 90 for women and 97 for men.\n* In the investigator's opinion, participants are reliable and willing and able to comply with the protocol requirements and procedures.\n* In addition to meeting the inclusion criteria outlined, it is important to develop a positive rapport between all individuals both participating in and coordinating the study.\n\nExclusion Criteria:\n\n* Any psychiatric, cardiovascular, neurological, or other disorders that may be aggravated by participation in the study, or complicate interpretation of the study's results.\n* Any substance use disorder.\n* For women, a positive pregnancy test, or not using a reliable method of birth control.\n* Personal or family history of severe psychiatric disorders (schizophrenia, bipolar disorder, addiction, ASD) and\u002For psychosis in the first and second degree.\n* During the interview family history is asked in detail. Example: Did your parents or grandparents received a diagnosis of schizophrenia, bipolar disorder, depression.... Did somebody die by suicide? ...Did somebody was hospitalized in a psychiatric hospital? Did somebody in the family was judged \"strange\"? Different? Even if 40 years ago the diagnosis of depression or bipolar disorder was less precise, do you have the impression that somebody was sick?\n* A resting blood pressure \\> 140 systolic and 90 diastolic (mmHg).\n* Cardiovascular diseases including valvulopathy.\n* Current tricyclic antidepressant, lithium, SSRIs, first- and second-generation ketamine antipsychotics, or MAOI prescription regimen.\n* Current dietary supplementation of 5-hydroxytryptophan and St. John's Wort.\n* Medically significant condition rendering unsuitability for the study (e.g., diabetes, epilepsy, severe cardiovascular disease, hepatic or renal failure e.g. CLRC \\\u003C 30 ml\u002Fmin etc.).\n* History of serious suicide attempts requiring hospitalization.\n* Significant history of mania (determined by study psychiatrist and medical records).\n* Psychiatric condition judged to be incompatible with establishment of rapport with therapy team and\u002For safe exposure to psilocybin, e.g. borderline personality disorder.\n* Blood or needle phobia.\n* Participants who do not agree to use an acceptable contraceptive method throughout their participation in study.\n* Use of contraindicated medication.","21 Years","65 Years",{"count":159,"type":21},50,[161],"PHASE1","In this study, participants will received either psilocybin (the active ingredient found in certain mushrooms) or an inactive placebo (a look-alike tablet with no active drug). The psilocybin is supplied by Filament Health (Burnaby, British Columbia).\n\nAfter psilocybin ingestion, the body quickly converts it into psilocin, which is the form that produces the temporary psychological effects. Psilocin mainly works by interacting with serotonin receptors in the brain, especially a type called the 5-HT2A receptor.\n\nThis study will be done in healthy volunteers using a single oral dose of 25 mg (one tablet by mouth), consistent with doses used in previous clinical research.\n\nThe goal is to understand the biological, psychological, and high-density EEG (hd-EEG) changes that can happen after a one-time dose of psilocybin.",[164,27,165],"Healthy Participants","Psilocybin",[167,168,169],"psychdelics","biomarkers","hd-EEG","2026-02-19",{"date":172,"type":33},"2026-02-25",{"date":174,"type":21},"2026-09-01",{"date":176,"type":21},"2029-09-01",{"name":178,"class":40},"Gabriella Gobbi",{"id":180,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":181,"targetDuration":4,"studyType":22,"phases":182,"briefSummary":25,"conditions":183,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":188,"leadSponsor":190,"locationsCount":41},"100596913",{"count":20,"type":21},[24],[27,28],"2026-01-06",{"date":186,"type":33},"2026-01-07",{"date":35,"type":33},{"date":189,"type":21},"2026-04",{"name":39,"class":40},{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":199,"minAge":87,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":4},"100617412","targeted-lidocaine-infusion-for-pain-reduction-in-office-hysteroscopy-100617412","NCT07318285","Targeted Lidocaine Infusion for Pain Reduction in Office Hysteroscopy","A Modified Technique of Target Lidocaine Infusion for Pain Control in Office Hysteroscopy: A Double-Blind Randomized Controlled","OPTILID","Inclusion Criteria:\n\n* Age \\> 18\n* Referred for outpatient diagnostic or operative (see-and-treat) hysteroscopy\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Pregnancy\n* Active pelvic inflammatory disease or cervicitis\n* Inability to consent\n* Anti-psychotic drugs usage\n* Previews cervical surgery (i.e., conization).\n* Any contraindication for office hysteroscopy- cervical malignancy, profuse uterine bleeding, invisible external os, recent uterine perforation.\n* Known allergy or hypersensitivity to Lidocaine","FEMALE",{"count":201,"type":21},208,[24],"The goal of this study is to find out whether a small amount of lidocaine (a common local anesthetic) can reduce pain during office hysteroscopy - a procedure used to look inside the uterus. The study will compare lidocaine to saline (salt water) to see which one helps more with pain relief.\n\nParticipants will:\n\n1. Receive either lidocaine or saline gently applied inside the cervix right before the procedure\n2. Undergo the hysteroscopy as planned\n3. Be asked to rate their pain and satisfaction after the procedure\n\nLidocaine is commonly and safely used in dental and gynecological procedures. Participation is voluntary, and the procedure itself will not change.",[205,206,27],"Hysteroscopy \u002F Methods","Lidocaine Infusion","2025-12-28",{"date":209,"type":33},"2026-01-05",{"date":211,"type":21},"2026-02-01",{"date":213,"type":21},"2029-12-30",{"name":215,"class":40},"YAARA TABIB",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":15,"sex":16,"minAge":87,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":22,"phases":227,"briefSummary":229,"conditions":230,"keywords":240,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":253},"100611785","phase-2-premedication-with-n-acetylcysteine-and-simethicone-to-improve-mucosal-visualization-in-elective-upper-endoscopy-100611785","NCT07245095","Premedication With N-acetylcysteine and Simethicone to Improve Mucosal Visualization in Elective Upper Endoscopy","Randomized Controlled Trial to Evaluate the Effect of Premedication With N-acetylcysteine and Simethicone on Mucosal Visibility During Elective Upper Gastrointestinal Endoscopy Using the TUGS Score","NACSIMET","Inclusion Criteria:\n\n* Men and women aged 18 to 70 years old.\n* Patients who agree to participate in the clinical trial.\n* Patients without active gastrointestinal bleeding.\n* Signing of informed consent form.\n\nExclusion Criteria:\n\n* Patients with a history of hypersensitivity to N-acetylcysteine\n* Patients with a history of hypersensitivity to simethicone\n* Patients with a previous endoscopic diagnosis\n* Patients with a history of gastric or bariatric surgery\n* Patients with a history of motor disorders (e.g., scleroderma, diabetic gastroparesis)\n* Patients taking medications that delay gastric emptying (GLP-1 analogues)\n* Pregnant or breastfeeding patients\n* Patients who do not agree to participate in the clinical trial","99 Years",{"count":226,"type":21},132,[228],"PHASE2","The goal of this randomized, double-blind, placebo-controlled clinical trial is to assess whether the combination of N-acetylcysteine and simethicone improves mucosal visibility during upper gastrointestinal endoscopy in adults aged 18 to 99 years of both sexes, including both healthy individuals and those with non-bleeding gastrointestinal symptoms.\n\nThe main questions this study aims to answer are:\n\nDoes pre-endoscopy administration of N-acetylcysteine\u002Fsimethicone improve mucosal visualization based on the Toronto Upper Gastrointestinal Cleanliness Score (TUGS)?\n\nIs this combination safe and well tolerated in this patient population?\n\nResearchers will compare patients receiving N-acetylcysteine (600 mg) and simethicone (100 mg) orally 20-60 minutes before the procedure with those receiving placebo (water) to determine if there is a significant improvement in TUGS scores.\n\nParticipants will:\n\nReceive a single oral dose of either N-acetylcysteine\u002Fsimethicone or placebo prior to endoscopy\n\nUndergo a routine upper GI endoscopy\n\nHave mucosal cleanliness evaluated using the TUGS scoring system\n\nBe monitored for any adverse events or intolerance",[231,232,233,234,235,236,27,237,238,239],"Esophagogastroduodenoscopy","Simethicone","N-Acetylcysteine","Premedication","Visualization","Esophagogastroduodensocopy (EGD) Procedure","Gastritis Associated With Helicobacter Pylori","Tumor Gastric","Lesions in the Esophagus, Stomach, Duodenum or Rectum",[231,241,234,232,242,243],"Mucous Membrane","Acetylcysteine","Gastrointestinal Tract","2025-11-20",{"date":246,"type":33},"2025-11-24",{"date":248,"type":33},"2025-09-12",{"date":250,"type":21},"2026-12-31",{"name":252,"class":40},"Hospital General de Mexicali",2,{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":15,"sex":16,"minAge":87,"maxAge":125,"enrollmentInfo":261,"targetDuration":4,"studyType":22,"phases":263,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":41},"100596957","the-influences-of-blood-flow-restriction-on-leg-press-100596957","NCT07052227","The Influences of Blood Flow Restriction on Leg Press","The Influences of Blood Flow Restriction on Leg Press Perceptual Responses and Performance, and Systemic Arterial Stiffness","Inclusion Criteria:\n\n1. Physically active (\\> 1,000 MET\u002Fmin\u002Fwk) for at least six months.\n2. Weight stable for previous 6 months (+\u002F-2.5 kg)\n\nExclusion Criteria:\n\n1. Stage 2 hypertension (SBP \\>\u002F= 140 and\u002For DBP \\>\u002F= 90 mmHg)\n2. BMI\\>40 kg\u002Fm2\n3. Diabetes\n4. Familial hypercholesterolemia\n5. Past or current history of CHD, stroke or major CVD events. Respiratory diseases (not including asthma), endocrine or metabolic, neurological, or hematological disorders that would compromise the study or the health of the subject.\n6. Participants must not be pregnant, plan to become pregnant during the study, or be nursing\n7. Active renal or liver disease\n8. All medications and supplements that influence dependent variables\\*\n9. Recent surgery \\\u003C 2 months\n10. Alcohol abuse\n11. Sleep apnea",{"count":262,"type":21},30,[24],"This study will investigate the use of different blood flow restriction cuffs during leg press exercise on arterial stiffness, muscle morphology, performance, and participant perception.",[266,267,27],"Delfi Cuff","Fitcuff","2025-06-26",{"date":270,"type":33},"2025-07-04",{"date":272,"type":21},"2025-09-01",{"date":274,"type":21},"2025-12-15",{"name":276,"class":40},"Salisbury University"]